Micellar Nanocarriers with Controlled Multivalent Ligand Presentation

具有受控多价配体呈现的胶束纳米载体

基本信息

  • 批准号:
    8583975
  • 负责人:
  • 金额:
    $ 18.46万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-07-05 至 2015-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In addition to the enhanced permeation and retention (EPR) effect, nanocarriers can be actively targeted to improve the efficacy of treatment and minimize side effects by surface grafting target ligands to impart an affinity for cellular upregulated receptors or components on tumor cells. However, the effects of the presence of a targeting moiety on the pharmacokinetics, biodistribution and tumor accumulation of nanocarriers still remain to be quantified and can be controversial in some cases. In addition to the biological factors such as tumor physiology, the influence of a targeting moiety on the in vivo pathway and fate of nanocarriers should depend on the nature of the targeting moiety as well as its spatial distribution on the nanocarrier surface. In contrast to well-regulated structural contrl seen in viruses, there is limited structural control in existing nanocarriers over the spatial distribution of ligands and the orientation of ligand relative to the particle surface that determies the availability of ligand binding sites. We have designed and synthesized so-called "3-helix micelles" that are uniform in size from 10-20 nm based on amphiphilic 3-helix peptide-polyethylene glycol (PEG) conjugates. The in vivo stability of the radiolabeled 3-helix micelles have been confirmed using positron emission tomography (PET) and the alpha circulatory half-life of PEGylated 15 nm micelle is ~28 h. 3-helix micelles already overcame several difficulties encountered to prepare effective nanocarriers such as size, cargo leakage, in vivo stability and clearance. Upon attaching target ligands to the surface of micelles, we should be able to achieve control over oligomeric state of ligand presentation. We propose to (1) synthesize ligand decorated nanocarriers, 10-20 nm in size with control over the inter-ligand distance and local multivalency of ligand presentation; (2) perform in vitro studies to evaluate the carrier internalization as a function of ligand density and multivalency; and (3) carry out in vivo studies use two cancer models, i.e. breast cancer and prostate cancer, to evaluate the effect of ligand density, inter-ligand distance and ligand clustering on the pharmacokinetics and biodistribution of these new 3-helix micelles. We will also perform immunogenicity tests on promising micellar nanoparticles to ensure their clinical viability as nanocarriers. Coiled-coil is the most common protein motif to control ligand presentation. The targeted micelles are ideal model system to answer several critical questions regarding the design principle of active targeting nanocarriers. Practically, our studies are based on micellar nanoparticles that have already demonstrated many desirable attributes as nanocarriers. Proposed studies may potentially lead to effective therapeutics with the combined advantages of both passive targeting via EPR effect and active targeting for breast tumors.
描述(由申请人提供):除了增强的渗透和保留(EPR)作用外,纳米载体还可以通过表面接枝靶配体以赋予对肿瘤细胞上细胞上调受体或组分的亲和力来主动靶向,以提高治疗功效并使副作用最小化。然而,靶向部分的存在对纳米载体的药代动力学、生物分布和肿瘤蓄积的影响仍有待量化,并且在某些情况下可能存在争议。除了诸如肿瘤生理学的生物学因素之外,靶向部分对体内肿瘤的影响也是重要的。 纳米载体的途径和命运应取决于靶向部分的性质及其在纳米载体表面上的空间分布。与病毒中观察到的良好调节的结构控制相反,现有纳米载体中对配体的空间分布和配体相对于颗粒表面的取向的结构控制有限,这决定了配体结合位点的可用性。 我们设计并合成了所谓的“3-螺旋胶束”,其基于两亲性3-螺旋肽-聚乙二醇(PEG)缀合物,尺寸均匀,从10-20 nm。放射性标记的3-螺旋胶束的体内稳定性已使用正电子发射断层扫描(PET)证实,聚乙二醇化15 nm胶束的α循环半衰期约为28 h。3-螺旋胶束已经克服了制备有效纳米载体所遇到的一些困难,如尺寸、货物泄漏、体内稳定性和清除率。在将目标配体连接到胶束表面后,我们应该能够实现对配体呈递的寡聚状态的控制。 我们建议(1)合成配体修饰的纳米载体,尺寸为10-20 nm,控制配体间距离和配体呈递的局部多价性;(2)进行体外研究以评估载体内化作为配体密度和多价性的函数;和(3)进行体内研究 使用两种癌症模型,即乳腺癌和前列腺癌,来评估配体密度、配体间距离和配体聚集对这些新的3-螺旋胶束的药代动力学和生物分布的影响。我们还将对有前途的胶束纳米颗粒进行免疫原性测试,以确保其作为纳米载体的临床可行性。卷曲螺旋是控制配体呈递的最常见的蛋白质基序。靶向胶束是回答主动靶向纳米载体设计原理中几个关键问题的理想模型体系。实际上,我们的研究是基于胶束纳米粒子,已经证明了许多理想的属性作为纳米载体。拟议的研究可能会导致有效的治疗方法,结合了通过EPR效应的被动靶向和乳腺肿瘤的主动靶向的优势。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ting Xu其他文献

Role of nasal microbiota in regulating host anti-influenza immunity in dogs
  • DOI:
    10.1186/s40168-025-02031-y
  • 发表时间:
    2025-01-27
  • 期刊:
  • 影响因子:
    12.700
  • 作者:
    Jinzhu Geng;Yuhao Dong;Hao Huang;Xia Wen;Ting Xu;Yanbing Zhao;Yongjie Liu
  • 通讯作者:
    Yongjie Liu

Ting Xu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ting Xu', 18)}}的其他基金

An Alignment Framework For Mapping Brain Dynamics and Substrates of Human Cognition Across Species
用于绘制跨物种大脑动态和人类认知基础的对齐框架
  • 批准号:
    10360863
  • 财政年份:
    2021
  • 资助金额:
    $ 18.46万
  • 项目类别:
Multimodal Data Analysis and Integration
多模态数据分析与集成
  • 批准号:
    10639548
  • 财政年份:
    2017
  • 资助金额:
    $ 18.46万
  • 项目类别:
Micellar Nanocarriers with Controlled Multivalent Ligand Presentation
具有受控多价配体呈现的胶束纳米载体
  • 批准号:
    8695347
  • 财政年份:
    2013
  • 资助金额:
    $ 18.46万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 18.46万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 18.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 18.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 18.46万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 18.46万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 18.46万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 18.46万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 18.46万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 18.46万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 18.46万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了